Cactus Life Sciences Bolsters Rare Disease Expertise With Nspm And EluSCIdate Acquisition

Cactus Life Sciences, a prominent scientific communications agency based in Princeton, New Jersey, has announced its acquisition of nspm and eluSCIdate, two Swiss-based medical communications and publications companies. This strategic move marks a significant expansion for Cactus Life Sciences, enhancing its global footprint and service offerings in the biopharma sector. The acquisition is poised to bolster the agency's capabilities in medical communications, publications, and event management, particularly in the realm of rare diseases.

Established in 2010, Cactus Life Sciences has become synonymous with innovative global operating models that emphasize science, innovation, and efficiency. nspm, with a 27-year history, brings to the table its deep expertise in medical communications and a strong focus on rare diseases—a field where individual conditions are rare but collectively impact over 300 million people worldwide. eluSCIdate, founded more recently in 2020, complements this expertise with its focus on medical and scientific publications.

Oliver Dennis, the newly appointed Chairman of Cactus Life Sciences, expressed enthusiasm about the acquisition, highlighting the shared values and vision between the companies. This collaboration aims to create a more integrated global approach to medical communications, significantly benefiting biopharma clients by addressing the unmet needs of patients with rare diseases.

Sabine Stotz, PhD, Managing Director at nspm, echoed this sentiment, emphasizing the alliance's potential to enrich the scientific communications landscape. Meanwhile, Elvira Dsouza, President of Cactus Life Sciences, pointed out the company's commitment to excellence and innovation. She underscored the importance of integrating advanced technology, including artificial intelligence (AI), to enhance scientific content creation and make healthcare information more accessible and impactful.

The combined expertise of Cactus Life Sciences, nspm, and eluSCIdate is expected to create a formidable force in the medical communications industry. This partnership not only signifies a major step forward in providing comprehensive services but also establishes a significant presence across the US, UK, Switzerland, and Japan. The focus on rare diseases underlines a commitment to addressing some of the most challenging areas in healthcare today.

About Cactus Life Sciences: Cactus Life Sciences is a leading medical communication company that offers scientific strategy and content across the healthcare continuum globally. It works closely with healthcare companies to optimize the role of medicines and foster positive outcomes for patients.

About nspm: Founded in 1997, nspm is a dynamic medical communications company with offices in Switzerland and the UK. It specializes in medical writing, project management, and strategic medical communications solutions across various therapeutic areas with an emphasis on rare diseases.

About eluSCIdate: eluSCIdate is a specialist medical writing agency founded in 2020. It focuses on scientific publications and supports clients throughout the publication process with high-quality manuscripts, posters, and slides.

This acquisition underscores a shared commitment to advancing healthcare communications and improving patient outcomes through scientific excellence and creative solutions. The collaboration between Cactus Life Sciences, nspm, and eluSCIdate sets a new benchmark for innovation and efficiency in the global scientific communications industry.